Blood Sampling for Research Related to Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00542230|
Recruitment Status : Enrolling by invitation
First Posted : October 11, 2007
Last Update Posted : February 24, 2020
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease.
Volunteers must be at least 8 years of old. Samples will be taken both from healthy volunteers and from volunteers who have unique red blood cell features that are related to sickle cell disease. Candidates will be screened with a medical history.
During the study, participants will undergo a one- to two-hour outpatient procedure at the National Institutes of Health Clinical Center. Once researchers have explained the study and obtained the participant s consent, participants will donate 8 cc (approximately 2 teaspoons) of blood.
Because repeat testing helps researchers validate study findings, participants who have the unique red blood cell features mentioned above may also be asked if they are willing to return and donate another 2 cc to 8 cc of blood for additional studies. The amount of blood drawn will not exceed 50 ml with any eight-week period for adults or 7 cc within any six-week period for children.
|Condition or disease|
|Sickle Cell Trait Sickle Cell Disease Sickle Cell Anemia|
|Study Type :||Observational|
|Actual Enrollment :||51 participants|
|Official Title:||High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease|
|Actual Study Start Date :||November 7, 2007|
Sickle Cell Trait
Patient with sickle cell trait or disease
- To screen large compound libraries for anti-sickling activity, particularly compounds that are already FDA-approved drugs, with the goal of discovering a drug for treating sickle cell disease. [ Time Frame: daily ]To identify by high sensitivity in vitro screening methods additional compounds that inhibit sickling
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00542230
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||William A Eaton, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|